• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Filaria journal >The Mectizan? Donation Program – highlights from 2005
【24h】

The Mectizan? Donation Program – highlights from 2005

机译：Mectizan ？ 捐赠计划-2005年的亮点

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Through the Mectizan? Donation Program, Merck & Co., Inc. has donated Mectizan (ivermectin, MSD) for the treatment of onchocerciasis worldwide since 1987. Mectizan has also been donated for the elimination of lymphatic filariasis (LF) since 1998 in African countries and in Yemen where onchocerciasis and LF are co-endemic; for LF elimination programs, Mectizan is co-administered with albendazole, which is donated by GlaxoSmithKline. The Mectizan Donation Program works in collaboration with the Mectizan Expert Committee/Albendazole Coordination, its scientific advisory committee. In 2005, a total of 62,201,310 treatments of Mectizan for onchocerciasis were approved for delivery via mass treatment programs in Africa, Latin America, and Yemen. Seventy-seven percent and 20% of these treatments for onchocerciasis were for countries included in the African Programme for Onchocerciasis Control (APOC) and the former-Onchocerciasis Control Programme in West Africa (OCP), respectively. The remaining 3% of treatments approved were for the six onchocerciasis endemic countries in Latin America, where mass treatment is carried out twice-yearly with the goal of completely eliminating morbidity and eventually transmission of infection, and for Yemen. All 33 onchocerciasis endemic countries where mass treatment with Mectizan is indicated have ongoing mass treatment programs. In 2005, 42,052,583 treatments of co-administered albendazole and Mectizan were approved for national Programs to Eliminate LF (PELFs) in Africa and Yemen. There are ongoing PELFs using albendazole and Mectizan in nine African countries and Yemen; these represent 35% of the total number of countries expected to require the co-administration of these two chemotherapeutic agents for LF elimination. In Africa, the expansion of existing PELFs and the initiation of new ones have been hampered by lack of resources, technical difficulties with the mapping of LF endemicity, and the co-endemicity of LF and loiasis. Included in this review are recommendations recently put forward for the co-administration of albendazole and Mectizan in areas endemic for LF, loiasis, and onchocerciasis.
机译：通过Mectizan？默克公司（Merck＆Co.，Inc.）的捐赠计划自1987年以来已经在世界范围内捐赠了Mectizan（伊维菌素，MSD）用于治疗盘尾丝虫病。自1998年以来，Mectizan还被捐赠用于消除淋巴丝虫病（LF）在非洲国家和也门盘尾丝虫病和LF是地方病;对于LF消除计划，Mectizan与由GlaxoSmithKline捐赠的albendazole并用。 Mectizan捐赠计划与Mectizan专家委员会/阿苯达唑协调委员会（科学咨询委员会）合作。 2005年，通过非洲，拉丁美洲和也门的大规模治疗计划，批准了总计62,201,310的Mectizan治疗盘尾丝虫病治疗。这些针对盘尾丝虫病的治疗分别有77％和20％用于非洲盘尾丝虫病控制计划（APOC）和前西非盘尾丝虫病控制计划（OCP）中的国家。批准的其余3％的治疗方法适用于拉丁美洲的6个盘尾丝虫病流行国家，该国每年进行两次大规模治疗，目的是完全消除发病率并最终消除传染病，以及也门。指示使用Mectizan进行大规模治疗的所有33个盘尾丝虫病流行国家都正在实施大规模治疗计划。 2005年，批准了阿苯达唑和Mectizan并用的42,052,583疗法被批准用于非洲和也门的国家消除LF（PELF）计划。 9个非洲国家和也门正在使用阿苯达唑和Mectizan进行PELF。这些占预期需要这两种化疗药物共同使用以消除LF的国家总数的35％。在非洲，现有的PELF的扩展和新PELF的启动因缺乏资源，绘制LF流行病的技术困难以及LF和疯牛病的共同流行而受到阻碍。该评价中包括最近提出的关于阿苯达唑和Mectizan在LF，loiasis和onchocerciasis的地方流行的建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号